See Testagen dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
Testagen is a Khavinson-family tetrapeptide (Lys-Glu-Asp-Gly) targeting testicular tissue and Leydig cell function, with reported preclinical effects on testosterone biosynthesis in aged rodent models. It sits in the same St. Petersburg Institute of Bioregulation framework as the broader Khavinson short-peptide family. This data shows the dose amounts, vial sizes, and diluent volumes researchers most commonly select when reconstituting Testagen.
Testagen is a synthetic tetrapeptide (Lys-Glu-Asp-Gly) developed at the St. Petersburg Institute of Bioregulation and Gerontology under Vladimir Khatskelevich Khavinson as part of the organ-specific short-peptide bioregulator program, with a specific tissue target: testicular tissue and Leydig cell function. Within the broader Khavinson framework — which proposes that very short organ-specific oligopeptides exert tissue-targeted epigenetic regulation by binding gene-promoter regions in the same tissue from which they were originally derived — Testagen is positioned as the synthetic peptide derived from the parent multi-peptide testicular extract, with the published Khavinson-group preclinical work focused on testosterone biosynthesis support and Leydig cell function in aged rodent models.
Testagen is a synthetic dipeptide (Glu-Trp) from the Khavinson short-peptide bioregulator program, sourced for male reproductive and androgen-aging research. It ships as a lyophilized powder you reconstitute with bacteriostatic water, and is catalogued with the same Glu-Trp sequence as the thymic peptide Thymogen.
In the Khavinson framework, Testagen is proposed to act through direct binding to gene-promoter DNA in testicular Leydig and Sertoli cells, selectively modulating transcription of genes involved in spermatogenesis, androgen biosynthesis, and apoptosis regulation. This proposed direct-DNA-binding mechanism is unconventional and has not been independently characterised outside the Khavinson group.
Russian single-site studies have reported Testagen in age-related androgen decline, oligospermia, and male infertility contexts in elderly patients, with reported improvements in sperm-count, motility, and androgen-axis markers versus standard care. These studies are not blinded or placebo-controlled, and no Western Phase 2 or 3 trial has been registered.
Testagen has a reported half-life of ~30 min (short-peptide estimate), and the dose intervals researchers model most often fall around once daily (in 10–20 day courses). This short Khavinson peptide clears within an hour with no systemic buildup; its bioregulator effect is thought to come from the full course rather than a steady level. It is catalogued under Testosterone Peptides on WPA.
21 Testagen reconstitution calculations have been logged by the WPA community. The most common dose entered is 100mcg (4 calculations). The median dose across all sessions is 2mg. The most common bacteriostatic water volume is 2mL. The most popular vial size is 20mg (20 sessions). The most common dosing frequency is daily (7x/week) (3 logged protocols).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.